Rx-360 An International Pharmaceutical Supply Chain Consortium

Similar documents
Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency

CHEM-E4140 Selectivity 12. Pharma Business

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Pharma working capital leaves room for improvement

In the largest and perhaps the most ambitious collaborative

Evolving tactical video production- Creative Studios

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Pharma working capital performance highly variable

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

Multiple Sclerosis Treatments: World Market Outlook to 2011

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

ehealthinsight Series: Online Patient Recruitment Strategies

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013

Biotechnology in North Carolina

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

1) SCOPE OF THE PROGRAM

THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS

The Gold Standard for Processing and Packaging

How companies leverage quality and quality certifications to achieve competitive advantage

INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS

Sage ERP I White Paper

Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor

THE BIOTECH & PHARMACEUTICAL INDUSTRY

GSK Public policy positions

Manufacturer of drug substance

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

To know more about Pharmacovigilance and Clinical Trials Data Management

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Annual Press Conference Business Year 2011

Rx-360 Supply Chain Security White Paper: Incident Management

Global Multiple Sclerosis Market: Trends and Opportunities ( )

Pharmaceutical Quality Systems (ICH Q10) Conference. Business Case for Quality

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

Pharmaceutical Distribution in the US: Current and Future Perspectives

PHARMACEUTICAL INDUSTRY PROFILE

Tuas Biomedical Park

GMP Pharma BV. Netherlands

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

Identity Management & Digital Signatures in the BioPharmaceutical Industry John Hendrix; Program Director CTST 2009

Value Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector

INCENTIVE COMPENSATION CONFERENCE

Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration

CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

CALCET Company California Consulting Engineering & Technology E14th St. Ste 340, San Leandro, CA USA

Published by Waterford Life Sciences, Washington, DC Cover and book design: Gretchen Maxwell, GLM Design

The Role Of Industry in the Australian Clinical Trials Sector

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Global Non-Small Cell Lung Cancer Therapeutics Market

Pharmaceutical Marketing Disclosures

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

APV/IPEC Europe Excipient Conference 2014

Egy magyar, nagynyomású hidrogén-generátor Perspektívák és alkalmazások idehaza és külföldön

EU Clinical Trials Register

Health Care Job Information Sheet #20. Clinical Research

Digital Leaders Deal With a Range of Organizational Challenges

KEEPING CLINICAL TRIALS IN AUSTRALIA

Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions

2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit

Accelerating Drug & Clinical Trial Approvals in China & East Asia

Global Pharmaceuticals Marketing Channel Reference EDITION

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pipeline, timeline, deadline

Main Conference Agenda

An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore

CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.

Roots Analysis Pvt. Ltd.

Black Mountain Consulting Group. Not just Knowledge..Know-How

Medical Writing Takes Off in India

van den Besselaar Mobile Phone no. : +31(0) leo.besselaar@lbqconsultancy.nl

The United States False Claims Act Qui Tam Whistleblower Law

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

How To Schedule A Lab

Pharmaceutical industry

Peter Erickson. C2 Healthcare CREATIVE DIRECTOR/COPY/CONTENT. Chicago. Creative Director/Senior Copywriter/Content Strategist

Resource Scheduling in QC Laboratories

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

GAMP5 - a lifecycle management framework for customized bioprocess solutions

New Jersey Bio-Pharmaceutical Life Sciences Landscape

Patterns and predictors of suicides in the U.S. Army: An introduction to the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)

from PKI to Identity Assurance

VAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY

Biopharmaceutical Raw Materials throughout the Product Lifecycle

The Board reviews risks to the Company s business plan at its scheduled meetings.

Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs

PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management

Medical Communication Companies and Industry Grants

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM

An integrated global healthcare company

Services Providers. Ivan Soto

Ross Career Services. Health Care. Introduction. Health Care Overview

Great Expectations: Enhanced Obligations in Recent HHS-OIG Corporate Integrity Agreements

Source: BIO, Factset, NASDAQ

Document and Quality Management Solutions for Life Sciences

ABCD. Welcome to BICI. Petersburg, Virginia

Transcription:

Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011

Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24) Abbott Amgen Amylin AstraZeneca Baxter Bayer Biogen Idec Boehringer Ingelheim BMS Cephalon Eli Lilly Forest Laboratories Roche/Genentech GSK Hospira Johnson & Johnson Mylan Inc. Merck & Co. Novartis Pfizer Sanofi-Aventis Takeda Teva Watson Suppliers (24) AMPAC Fine Chemicals LLC Arch Pharmalab (USA) Inc. Avantor Performance Materials, Inc. BASF Doe & Ingalls DSM Nutritional Products Ltd Fagron GE Healthcare Hikal Hovione ISP Labochim LifeConEx Life Technologies Corp. Merck KGaA Novozymes OSO BioPharmaceuticals Manufacturing LLC SICPA Sigma Aldrich Spectrum Chemical & Laboratory Products TempTime VWR West York Container 2

Rx-360 Observers (Continuously updated list at www.rx-360.org) Auditors (7) PSC Biotech Corp. Regulatory Compliance Associates RMC Pharmaceutical Solutions Inc. Safis Solutions LLC SQA Services Inc. The Weaver Group, Inc. Auckerman Consulting Associations (11) APIC Bulk Pharmaceutical Task Force Clinton Health Access Initiative, Inc. Council for Responsible Nutrition European Fine Chemicals Group (EFCG) European Generic Medicines Association (EGA) IPEC Americas IPEC Europe NSD Bio Group Parenteral Drug Association (PDA) Pharmaceutical Quality Group (PQG) 3

Eligibility for Membership in Rx-360 http://www.rx-360.org/membership/joinrx360today/tabid/144/default.aspx The following entities are eligible to become Members, subject to exceptions noted below: manufacturers of pharmaceutical or biotechnology finished products; suppliers of ingredients and components of pharmaceutical or biotechnology products; and suppliers of services relating to the quality or safety of the pharmaceutical or biotechnology supply chain. Exceptions: Providers of auditing services concerning the quality systems for, and quality of, pharmaceutical or biotechnology products, ingredients or components are not eligible for Rx- 360 membership. Providers of auditing services are eligible to become Observers of Rx- 360. Consultants are not eligible for Rx-360 membership. The following types of entities are eligible to become Observers of Rx-360: a governmental unit or quasi-governmental unit; a non-profit trade or professional association comprised of (a) pharmaceutical or biotechnology manufacturers, (b) suppliers of pharmaceutical/biotechnology ingredients or components, (c) suppliers of services relating to the quality or safety of the pharmaceutical or biotechnology supply chain, and/or (d) individuals employed by or whose activities relate to the pharmaceutical or biotechnology industries; and auditors of the quality systems for, and quality of, pharmaceutical or biotechnology products, ingredients or components. 4

How to Become a Member http://www.rx-360.org/membership/joinrx360today/tabid/144/default.aspx For Manufacturers and Suppliers: Review the Rx-360Antitrust/Anticompetitive Policy Review the Rx-360Bylaws. Sign and submit Membership Agreement to Rx-360 Secretariat For Observers Review the Rx-360Antitrust/Anticompetitive Policy Review the Rx-360Bylaws. Sign and submit Observer Agreement to Rx-360 Secretariat 5

By-laws and Agreements -- General http://www.rx-360.org/membership/joinrx360today/tabid/144/default.aspx Rx-360 By-laws Membership Agreement Observer Agreement Anti-trust/Anti-competitive Policy 6

Agreements for Participation in Audit Sharing Program Accessed through Rx-360 Database Membership Supplemental Confidentiality Agreement Between pharmaceutical manufacturer member or supplier member and Rx-360 Confidential Disclosure Agreement (CDA) Concerning Audit by Individual Rx-360 Member Between supplier and Rx-360 7

Agreements for Participation in Audit Sharing Program (Diagram) Pharma and Suppliers (Rx-360 Members) Suppliers (Rx-360 Members and Non-members) Membership Supplemental Confidentiality Agreement CDA for Audit by Individual Rx-360 Member Rx-360 Secretariat 8

Audit Sharing Concept Share reports and responses from audits conducted by individual member companies (not by Rx-360) Companies decide individually how to use information in the audit reports/responses Suppliers can exclude specific companies (i.e., competitors) from viewing the audit reports/responses Suppliers can also vet new members joining Rx-360 who have requested access to a Shared audit report 9 9

Benefits of Sharing Audit Reports for Sponsors and Suppliers Leveraging Information Already Available Provides a Broader Picture of Quality Culture and Performance Potential for Reducing Frequency and/or Length of Audits (Routine/Due Diligence) Identify and Pre-screen New Suppliers Promote Capabilities to Consortium Competitive Advantage and Visibility to Potential Customers 10

Audit Sharing Process: Overview Sponsor & Supplier agree to share audit report/responses Sponsor & Supplier Redact reports/responses Rx-360 uploads reports/responses into database (documents controlled by CDAs) 11

Audit Sharing Process: Detail (Scope and process described in further detail in Rx-360 SOPs) Plan to Share Audit Agree to Share Audit Report (and Responses) Redact Audit Report (and Responses) Share Audit Report (and Responses) Sponsors sign CDA Sponsors identify and contact suppliers that they will audit during the year Sponsors inform suppliers of the audit sharing program and ask them to participate Sponsors register suppliers in database Supplier reviews audit sharing information and speaks with Sponsor and/or Coordinator Supplier agrees to share audit report and responses (this can be done prior to or after the audit report is issued) Supplier signs CDA and identifies Rx-360 member companies that are allowed access to report/responses Sponsor redacts audit report and sends to supplier Supplier redacts audit report (if needed) and sends to Coordinator Coordinator uploads audit report into database 12 12

Rx-360 Database (1) Accessible to Rx-360 members Managed according to a Database Protocol describing, e.g., Change management (for the database) Security Disaster recovery Naming conventions Two main sections: Consortium internal documents (e.g, minutes, slides) Shared and Join Audit Program materials 13

Rx-360 Database (2) Shared Audit Program Materials Quality Management System (Quality Manual) Audit Reports and Responses Shared Audits Standard Operating Procedures (SOPs) Database protocol Signed Agreements Membership Suppliers 14

Quality Management System (QMS) Accessed through Rx-360 database Describes the Rx-360 Quality Policy Describes the Rx-360 Code of Ethics Describes policies for Developing Rx-360 procedures Governance Roles and responsibilities Audit processes Integrates and describes the Audit Sharing and Joint Audits goals and processes Describes key aspects and purpose of database Describes document management Describes and refers to forms, templates, SOPs, protocols, and agreements relevant to audit programs 15